Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Receptors & Signal Transduction|January 1, 1997
The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alphaR H Lipsky, D M Eckert, Y Tang, et al.Journal of Neurochemistry|April 1, 1992
Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytesA M Marini, R H Lipsky, J P Schwartz, et al.The Journal of Biological Chemistry|May 5, 1989
Isolation and characterization of platelet glycoprotein IV (CD36)N N Tandon, R H Lipsky, W H Burgess, et al.British Journal of Pharmacology|May 24, 2007
Mutations at F637 in the NMDA receptor NR2A subunit M3 domain influence agonist potency, ion channel gating and alcohol actionH Ren, A K Salous, J M Paul, et al.The Journal of Biological Chemistry|February 25, 1994
Identification of a human CD36 isoform produced by exon skipping. Conservation of exon organization and pre-mRNA splicing patterns with a CD36 gene family member, CLA-1Y Tang, K T Taylor, D A Sobieski, et al.Journal of Neurochemistry|July 20, 2001
Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotectionR H Lipsky, K Xu, D Zhu, et al.British Journal of Pharmacology|October 1, 2009
Differential actions of ethanol and trichloroethanol at sites in the M3 and M4 domains of the NMDA receptor GluN2A (NR2A) subunitA K Salous, H Ren, K A Lamb, et al.Blood|June 15, 1994
Identification of molecular defects in a subject with type I CD36 deficiencyH Kashiwagi, Y Tomiyama, S Kosugi, et al.Thrombosis and Haemostasis|August 1, 1995
Family studies of type II CD36 deficient subjects: linkage of a CD36 allele to a platelet-specific mRNA expression defect(s) causing type II CD36 deficiencyH Kashiwagi, Y Tomiyama, S Kosugi, et al.Amino Acids|February 17, 2005
Genomics and variation of ionotropic glutamate receptors: implications for neuroplasticityR H Lipsky, X Jiang, K Xu, et al.Pageof 3